• SNORA38B Drives NSCLC Progression and Immunotherapy Resistan

  2026-06-14

  This study identifies SNORA38B as an oncogenic snoRNA that promotes non-small cell lung cancer (NSCLC) growth and immune evasion through the GAB2/AKT/mTOR pathway. Targeting SNORA38B with locked nucleic acids sensitizes tumors to immune checkpoint blockade, highlighting its potential as a therapeutic target and biomarker.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-06-13

  The referenced study uncovers that MLKL polymerization directly induces lysosomal membrane permeabilization (LMP), leading to the release of cathepsin B and subsequent execution of necroptosis. This mechanistic insight clarifies the pivotal role of lysosomal proteases in cell death and highlights new experimental strategies for dissecting regulated necrosis in disease models.

• Antimycin A4: Expanding Mitochondrial Research with Dual Inh

  2026-06-12

  Explore how Antimycin A4, a potent ATP-citrate lyase inhibitor, redefines precision in mitochondrial and metabolic research. This article uniquely dissects practical assay implications and protocol strategies beyond standard applications.

• Tacalcitol Monohydrate: Applied Workflows in Cancer & Skin M

  2026-06-12

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, delivers reproducible gene regulation and NGF induction with low toxicity. Its versatility makes it a gold-standard tool for dermatological and oncology research, especially when optimizing anticancer synergy or nerve growth factor assays.

• Dual-Action Kinase Inhibitors Enhance p38α MAPK Dephosphoryl

  2026-06-11

  This study demonstrates that certain kinase inhibitors can simultaneously block kinase activity and stimulate p38α MAP kinase dephosphorylation by stabilizing a specific inactive conformation. These findings introduce a new dual-action mechanism for kinase inhibitors, with significant implications for improving inhibitor potency and selectivity in cell signaling and cancer research.

• CA-074 Me: Precision Cathepsin B Inhibitor for Lysosomal Res

  2026-06-11

  CA-074 Me empowers researchers to dissect lysosomal pathways, apoptosis, and necroptosis with unmatched selectivity and membrane permeability. Its robust inhibition profile and proven performance in complex cell death models make it indispensable for advanced cell biology and inflammation research.

• AEBSF.HCl in Necroptosis and Amyloid Research: Applied Proto

  2026-06-10

  AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) enables precise, reproducible inhibition of serine proteases in advanced models of necroptosis and amyloidogenic pathways. This guide distills cutting-edge assay strategies, troubleshooting essentials, and recent mechanistic breakthroughs to empower translational research.

• Dual-Fluorescence mRNA Delivery: Deep Dive into EZ Cap™ Cy5

  2026-06-10

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables precise, real-time mRNA delivery and translation analysis with dual-fluorescence technology. This article unpacks unique assay strategies, mechanistic innovations, and practical advances distinct from prior coverage.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-06-09

  This study introduces a new class of allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), a key regulator in metabolic diseases. The lead compound, 8c, demonstrates potent in vitro and in vivo activity, offering promising implications for oral treatment of diabetes, allergic disorders, and cancer.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-06-09

  Clasto-Lactacystin β-lactone stands out as a highly potent, cell-permeable, and irreversible proteasome inhibitor, enabling researchers to dissect the ubiquitin-proteasome system with unmatched specificity. This article streamlines advanced workflows, troubleshooting, and translational insights—empowering robust experimental design in virology, cancer, and neurodegeneration research.

• Integrating High-Throughput Screens for Antibacterial Target

  2026-06-08

  Santa Maria et al. introduce a machine learning framework that links phenotypic and biophysical screening data to identify mechanisms of action and novel inhibitors against Mycobacterium tuberculosis dihydrofolate reductase. This methodology advances antibacterial target discovery by systematically associating chemical features with bioactivity and target engagement, offering a blueprint for rational antibiotic development.

• AMD-070 Hydrochloride: CXCR4 Antagonist for Targeted Researc

  2026-06-08

  Mavorixafor hydrochloride (AMD-070 hydrochloride) empowers precision studies of CXCR4-driven pathways, enabling researchers to dissect cell migration, immune modulation, and viral entry with robust selectivity and solubility. APExBIO’s formulation is optimized for reproducibility in both hematologic and virology workflows, offering actionable advantages for translational and disease-modeling research.

• Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog in Appli

  2026-06-07

  Tacalcitol monohydrate empowers researchers with a synthetic analog of vitamin D3 for reproducible modulation of gene expression, NGF induction, and enhanced chemotherapy efficacy. Its low calcemic toxicity and versatility across dermatology and oncology set it apart for advanced translational workflows.

• Optimizing Alzheimer’s Models with Amyloid Beta-peptide (25-

  2026-06-06

  This article guides researchers on leveraging Amyloid Beta-peptide (25-35) (human) (SKU A1039) for consistent and reproducible Alzheimer’s disease neurotoxicity models. Drawing on recent mechanistic data and validated protocols, it addresses real-world challenges in assay design, microglial polarization, and product selection, ensuring robust outcomes for neurodegenerative disease research.

• Biomimetic Chromatography for Modeling Pulmonary Drug Permea

  2026-06-05

  Dillon et al. introduce a comparative approach using biomimetic open tubular capillary electrochromatography and immobilised artificial membrane chromatography coupled with mass spectrometry to model lung permeability of pharmaceuticals. Their findings reveal method-specific strengths for high-throughput permeability screening and underscore the nuanced interplay of drug physicochemical properties in pulmonary absorption.

456 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page